Immix Biopharma
IMMX
35 hedge funds and large institutions have $15.6M invested in Immix Biopharma in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 7 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
188% more capital invested
Capital invested by funds: $5.43M → $15.6M (+$10.2M)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
25% more funds holding
Funds holding: 28 → 35 (+7)
15.91% more ownership
Funds ownership: 4.02% → 19.93% (+16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$6.02M |
| 2 |
BL
Bleichroeder LP
New York
|
+$3.29M |
| 3 |
CCC
Cable Car Capital
San Francisco,
California
|
+$2.6M |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$1.57M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$710K |
| 2 |
MAWA
Moss Adams Wealth Advisors
Seattle,
Washington
|
-$138K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$128K |
| 4 |
Jane Street
New York
|
-$103K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$72K |
IMMX Hedge Fund Activity: Q1 2024 in Review
35 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2024, worth a combined $15.6M — up 188% from $5.43M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMMX positions and 7 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $6.02M. The largest seller was EAM Investors, exiting entirely with an estimated $710K sold.
- 35 institutional investors held Immix Biopharma (IMMX) as of Q1 2024, up from 28 in Q4 2023.
- Funds reported $15.6M of Immix Biopharma stock for Q1 2024, up 188% quarter-over-quarter.
- 14 funds opened new Immix Biopharma positions in Q1 2024 and 7 closed out, a net change of +7 holders.
- The largest Immix Biopharma buyer in Q1 2024 was AIGH Capital Management, an estimated $6.02M added.
- The largest Immix Biopharma seller in Q1 2024 was EAM Investors, an estimated $710K sold.
Based on aggregated 13F filings for Q1 2024.